FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2115728500> ?p ?o ?g. }

• W2115728500 endingPage "2534" @default.
• W2115728500 startingPage "2528" @default.
• W2115728500 abstract "Five hundred thirty-seven patients were enrolled in two independent, investigator-blinded, multicenter, randomized clinical trials comparing the clinical and bacteriologic efficacies and the safety of 5- or 10-day treatment with cefuroxime axetil with those of 10-day treatment with amoxicillin-clavulanate in the treatment of secondary bacterial infections of acute bronchitis. Patients received either 5 or 10 days of treatment (n = 177 in each group) with cefuroxime axetil at 250 mg twice daily or 10 days of treatment (n = 183) with amoxicillin-clavulanate at 500 mg three times daily. Patients in the cefuroxime axetil (5 days) group received placebo on days 6 to 10. Bacteriologic assessments were based on sputum specimen cultures obtained preceding and, when possible, following treatment. Organisms were isolated from the pretreatment sputum specimens of 242 of 537 (45%) patients, with the primary pathogens being Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, Streptococcus pneumoniae, and Staphylococcus aureus (28, 25, 13, 9, and 8% of isolates, respectively). Pathogens were eradicated or presumed to be eradicated in 87% (52 of 60), 91% (53 of 58), and 86% (60 of 70) of bacteriologically evaluable patients treated with cefuroxime axetil (5 days), cefuroxime axetil (10 days), and amoxicillin-clavulanate, respectively. A satisfactory clinical outcome (cure or improvement) was achieved in 82% (107 of 130), 86% (117 of 136), and 83% (130 of 157) of the clinically evaluable patients treated with cefuroxime axetil (5 days), cefuroxime axetil (10 days), and amoxicillin-clavulanate, respectively. Treatment with amoxicillin-clavulanate was associated with a significantly higher incidence of drug-related adverse events than was treatment with cefuroxime axetil for either 5 or 10 days (P = 0.001), primarily reflecting a higher incidence of drug-related gastrointestinal adverse events (37 versus 19 and 15%, respectively; P < 0.001), particularly diarrhea and nausea. These results indicate that treatment with cefuroxime axetil at 250 mg twice daily for 5 days is as effective as treatment for 10 days with either the same dose of cefuroxime axetil or amoxicillin-clavulanate at 500 mg three times daily in patients with acute bronchitis. In addition, treatment with cefuroxime axetil for either 5 or 10 days is associated with significantly fewer gastrointestinal adverse events, particularly diarrhea and nausea, than is 10-day treatment with amoxicillin-clavulanate." @default.
• W2115728500 created "2016-06-24" @default.
• W2115728500 creator A5027687514 @default.
• W2115728500 creator A5032535811 @default.
• W2115728500 creator A5034012171 @default.
• W2115728500 creator A5034849279 @default.
• W2115728500 creator A5035650443 @default.
• W2115728500 creator A5041396658 @default.
• W2115728500 creator A5068133313 @default.
• W2115728500 creator A5091425034 @default.
• W2115728500 date "1995-11-01" @default.
• W2115728500 modified "2023-10-16" @default.
• W2115728500 title "Effectiveness of short-course therapy (5 days) with cefuroxime axetil in treatment of secondary bacterial infections of acute bronchitis" @default.
• W2115728500 cites W124005684 @default.
• W2115728500 cites W1581962345 @default.
• W2115728500 cites W1967571838 @default.
• W2115728500 cites W1975582762 @default.
• W2115728500 cites W1993220990 @default.
• W2115728500 cites W2014335701 @default.
• W2115728500 cites W2015045556 @default.
• W2115728500 cites W2029820126 @default.
• W2115728500 cites W2029976029 @default.
• W2115728500 cites W2036896708 @default.
• W2115728500 cites W2054744155 @default.
• W2115728500 cites W2056315202 @default.
• W2115728500 cites W2057821365 @default.
• W2115728500 cites W2058231634 @default.
• W2115728500 cites W2062593222 @default.
• W2115728500 cites W206828689 @default.
• W2115728500 cites W2069259517 @default.
• W2115728500 cites W2075292748 @default.
• W2115728500 cites W2081200134 @default.
• W2115728500 cites W2084291992 @default.
• W2115728500 cites W2092243959 @default.
• W2115728500 cites W2099341493 @default.
• W2115728500 cites W2120110437 @default.
• W2115728500 cites W2163920914 @default.
• W2115728500 cites W2407354850 @default.
• W2115728500 cites W2409325940 @default.
• W2115728500 cites W34568296 @default.
• W2115728500 cites W2526329160 @default.
• W2115728500 doi "https://doi.org/10.1128/aac.39.11.2528" @default.
• W2115728500 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/162978" @default.
• W2115728500 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8585739" @default.
• W2115728500 hasPublicationYear "1995" @default.
• W2115728500 type Work @default.
• W2115728500 sameAs 2115728500 @default.
• W2115728500 citedByCount "32" @default.
• W2115728500 countsByYear W21157285002014 @default.
• W2115728500 countsByYear W21157285002015 @default.
• W2115728500 countsByYear W21157285002016 @default.
• W2115728500 countsByYear W21157285002017 @default.
• W2115728500 countsByYear W21157285002020 @default.
• W2115728500 countsByYear W21157285002021 @default.
• W2115728500 countsByYear W21157285002022 @default.
• W2115728500 crossrefType "journal-article" @default.
• W2115728500 hasAuthorship W2115728500A5027687514 @default.
• W2115728500 hasAuthorship W2115728500A5032535811 @default.
• W2115728500 hasAuthorship W2115728500A5034012171 @default.
• W2115728500 hasAuthorship W2115728500A5034849279 @default.
• W2115728500 hasAuthorship W2115728500A5035650443 @default.
• W2115728500 hasAuthorship W2115728500A5041396658 @default.
• W2115728500 hasAuthorship W2115728500A5068133313 @default.
• W2115728500 hasAuthorship W2115728500A5091425034 @default.
• W2115728500 hasBestOaLocation W21157285001 @default.
• W2115728500 hasConcept C126322002 @default.
• W2115728500 hasConcept C141071460 @default.
• W2115728500 hasConcept C142724271 @default.
• W2115728500 hasConcept C2776301714 @default.
• W2115728500 hasConcept C2776551000 @default.
• W2115728500 hasConcept C2776925733 @default.
• W2115728500 hasConcept C2777033495 @default.
• W2115728500 hasConcept C2777514703 @default.
• W2115728500 hasConcept C2779708577 @default.
• W2115728500 hasConcept C2779993553 @default.
• W2115728500 hasConcept C2781069245 @default.
• W2115728500 hasConcept C3019249092 @default.
• W2115728500 hasConcept C501593827 @default.
• W2115728500 hasConcept C71924100 @default.
• W2115728500 hasConcept C86803240 @default.
• W2115728500 hasConcept C89423630 @default.
• W2115728500 hasConcept C90924648 @default.
• W2115728500 hasConceptScore W2115728500C126322002 @default.
• W2115728500 hasConceptScore W2115728500C141071460 @default.
• W2115728500 hasConceptScore W2115728500C142724271 @default.
• W2115728500 hasConceptScore W2115728500C2776301714 @default.
• W2115728500 hasConceptScore W2115728500C2776551000 @default.
• W2115728500 hasConceptScore W2115728500C2776925733 @default.
• W2115728500 hasConceptScore W2115728500C2777033495 @default.
• W2115728500 hasConceptScore W2115728500C2777514703 @default.
• W2115728500 hasConceptScore W2115728500C2779708577 @default.
• W2115728500 hasConceptScore W2115728500C2779993553 @default.
• W2115728500 hasConceptScore W2115728500C2781069245 @default.
• W2115728500 hasConceptScore W2115728500C3019249092 @default.
• W2115728500 hasConceptScore W2115728500C501593827 @default.
• W2115728500 hasConceptScore W2115728500C71924100 @default.
• W2115728500 hasConceptScore W2115728500C86803240 @default.
• W2115728500 hasConceptScore W2115728500C89423630 @default.

• next